RecruitingNCT05870969

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

Exploration of A Holistic Management Procedure for Liver Cancer Surveillance in Improving Liver Cancer's Early Diagnosis Efficacy in Chinese Population: Single-Center, Prospective, Observational Real-world Study in EASTERN China


Sponsor

Ruijin Hospital

Enrollment

20,000 participants

Start Date

Mar 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a digital surveillance program using advanced liver imaging, blood tests, and AI-assisted analysis to improve the early detection of liver cancer in people who are at high risk due to chronic liver disease. **You may be eligible if...** - You are between 18 and 75 years old - You have chronic hepatitis B or C, cirrhosis (liver scarring), alcoholic or fatty liver disease, or other liver conditions that raise your risk of liver cancer - You are willing to attend regular monitoring visits **You may NOT be eligible if...** - You have already been diagnosed with liver cancer - You are not willing or able to complete the required follow-up visits - You have conditions that make liver imaging unsafe or uninterpretable Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALLiver cancer surveillance every 3 months

Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

BEHAVIORALLiver cancer surveillance every 6 months

Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

BEHAVIORALLiver cancer surveillance annually

Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam


Locations(1)

Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05870969


Related Trials